Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Breast Neoplasms 2Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 11Cisplatin 9Oxaliplatin 7Leucovorin 6Irinotecan 6Fluorouracil 5Taxes 3Radiotherapy 3Platinum 3Interleukin-12 Subunit p35 3Erlotinib Hydrochloride 3Capecitabine 3Albumin-Bound Paclitaxel 31,2-diaminocyclohexaneplatinum II citrate 3Trastuzumab 2Docetaxel 2Carboplatin 2130-nm albumin-bound paclitaxel 2tipifarnib 1sargramostim 1pembrolizumab 1motexafin gadolinium 1merestinib 1guadecitabine 1entinostat 1durvalumab 1dehydroftorafur 1aldesleukin 1Thalidomide 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gallbladder Neoplasms × merestinib × Clear all
NCT03027284 2020-05-19

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
19 enrolled
GastrointestinalLymphoid

Gallbladder Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡